Department of Intentional Ultrasound, Chinese Liberation Army General Hospital, Beijing, China.
Ultrasound Med Biol. 2013 Sep;39(9):1571-9. doi: 10.1016/j.ultrasmedbio.2013.03.030. Epub 2013 Jul 3.
The purpose of this study was to evaluate the clinical utility of low-mechanical-index contrast-enhanced ultrasound (CEUS) in assessing the response to percutaneous microwave ablation in patients with hepatocellular carcinoma by comparing the results with those of contrast-enhanced magnetic resonance imaging (CEMRI). Between August 2005 and July 2011, 182 patients with 231 lesions treated by microwave ablation were included in the study. One month after microwave ablation, CEUS and CEMRI were performed to evaluate therapeutic responses. The difference in diagnostic accuracy between the two methods was analyzed to evaluate the value of contrast-enhanced ultrasound after microwave ablation. The final diagnosis was based on computed tomography and MRI typical findings of therapeutic response of hepatocellular carcinoma, proven serum tumor marker levels and additional follow-up. The sensitivity of CEUS and CEMRI in evaluating the therapeutic effect of hepatocellular carcinoma was 86.5% and 84.6%; the specificity, 98.3% and 98.9%; and the accuracy, 95.7% and 95.7%.There was no significant statistical disparity between CEUS and CEMRI (p > 0.05).The sensitivity, specificity and accuracy were 98.1, 97.2 and 97.8% when CEUS was used in combination with CEMRI to evaluate the therapeutic response of hepatocellular carcinoma to microwave ablation. CEUS examination was proven to be a tolerable and easy modality for assessment of the therapeutic effect of microwave ablation and can provide results comparable to those obtained with CEMRI. Combining the results of these two examinations may reduce false-positive and false-negative diagnoses.
本研究旨在通过对比增强磁共振成像(CEMRI)评估经皮微波消融治疗肝细胞癌的疗效,评估低机械指数超声造影(CEUS)在评估该治疗反应中的临床应用价值。2005 年 8 月至 2011 年 7 月,我们共纳入 182 例 231 个病灶接受微波消融治疗的患者。微波消融治疗后 1 个月,行 CEUS 和 CEMRI 检查以评估疗效。分析两种方法诊断准确性的差异,以评估微波消融治疗后增强超声的价值。最终诊断依据为:CT 和 MRI 典型的肝癌治疗反应表现、肿瘤标志物水平和额外随访的综合判断。CEUS 和 CEMRI 评估肝癌治疗效果的灵敏度分别为 86.5%和 84.6%;特异度分别为 98.3%和 98.9%;准确率分别为 95.7%和 95.7%。CEUS 和 CEMRI 之间无统计学差异(p>0.05)。CEUS 联合 CEMRI 评估肝癌微波消融疗效的灵敏度、特异度和准确率分别为 98.1%、97.2%和 97.8%。CEUS 检查是一种评估微波消融治疗效果的可耐受、简便的方法,可获得与 CEMRI 相似的结果。联合两种检查结果可能减少假阳性和假阴性诊断。